ICLR:NGS-ICON plc (USD)

EQUITY | Diagnostics & Research | Nasdaq Global Select

Last Closing

USD 179.07

Change

-1.04 (-0.58)%

Market Cap

USD 4.25B

Volume

1.24M

Analyst Target

USD 199.20
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Icon PLC is a contract research organization that provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-28 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

N/A

USD 33.82B
NTRA Natera Inc

N/A

USD 21.03B
ILMN Illumina Inc

N/A

USD 14.06B
MEDP Medpace Holdings Inc

N/A

USD 9.97B
EXAS EXACT Sciences Corporation

N/A

USD 8.47B
GH Guardant Health Inc

N/A

USD 4.85B
RDNT RadNet Inc

N/A

USD 3.68B
SHC Sotera Health Co

N/A

USD 3.23B
WGS GeneDx Holdings Corp.

N/A

USD 2.75B
VCYT Veracyte Inc

N/A

USD 2.48B

ETFs Containing ICLR

XGES:LSE Xtrackers MSCI Genomic He.. 4.62 % 0.00 %

N/A

N/A
XGEN:XETRA Xtrackers MSCI Genomic He.. 4.57 % 0.00 %

N/A

N/A
PCIG Litman Gregory Funds Trus.. 4.52 % 0.00 %

N/A

USD 0.03B
BBH VanEck Biotech ETF 3.11 % 0.35 %

N/A

USD 0.40B
WELL:PA HAN-GINS Indxx Healthcare.. 3.02 % 0.00 %

N/A

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 3.02 % 0.00 %

N/A

N/A
EQQJ:LSE Invesco NASDAQ Next Gener.. 1.83 % 0.00 %

N/A

N/A
EQQJ:SW Invesco NASDAQ Next Gener.. 1.78 % 0.00 %

N/A

N/A
JNDQ:AU BETAJNDQ ETF UNITS 1.77 % 0.00 %

N/A

N/A
EIRL iShares MSCI Ireland ETF 0.00 % 0.47 %

N/A

USD 0.06B
GNRX 0.00 % 0.55 %

N/A

N/A
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
QQQN 0.00 % 0.00 %

N/A

N/A
IREMF 0.00 % 0.00 %

N/A

N/A
IRESF iShares Public Limited Co.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -14.61% 59% D- 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.61% 59% D- 37% F
Trailing 12 Months  
Capital Gain -46.70% 32% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -46.70% 32% F 23% F
Trailing 5 Years  
Capital Gain 32.61% 72% C 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 32.61% 72% C 47% F
Average Annual (5 Year Horizon)  
Capital Gain 9.91% 63% D 63% D
Dividend Return 9.91% 63% D 61% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 31.09% 90% A- 59% D-
Risk Adjusted Return 31.86% 85% B 64% D
Market Capitalization 4.25B 95% A 95% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 17.20 57% 48%
Price/Book Ratio 1.57 56% 55%
Price / Cash Flow Ratio 11.61 31% 26%
Price/Free Cash Flow Ratio 11.51 28% 32%
Management Effectiveness  
Return on Equity 8.44% 89% 73%
Return on Invested Capital 7.86% 91% 71%
Return on Assets 4.50% 91% 83%
Debt to Equity Ratio 35.67% 41% 48%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.